Company intelligence / Profile preview

Gene PreDiT

Ownership: Private
Development stage: Preclinical

Overview

Gene PreDiT is developing a targeted therapy for obesity using a novel genetic biomarker to identify patients most likely to benefit. The company has completed or was conducting a Phase IIa proof-of-concept clinical trial to validate both the efficacy of its compound and the predictive value of its biomarker. The approach aims at personalized treatment, improving outcomes by matching therapies to patient subgroups identified via genetic testing. No published results from later-stage trials are available.

Therapeutic areas: Metabolic Disorders
Modalities: Small molecules (drug repurposing approach)
Industry: Biotech

Drug pipeline

1 asset

GPP846

Unknown

Partnerships

Seeking co-development partners and licensing opportunities with pharmaceutical companies focused on obesity therapies; no specific partnerships named.

Beyond the preview

Go deeper on Gene PreDiT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gene PreDiT.